Clinical Trials

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03428802 2026-04-03

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

21 enrolled 9 charts

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT07290894 2026-04-02

MITO VULVA-01

80 enrolled

Vulvar Neoplasms

NCT05036681 2026-03-27

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Phase 2 Terminated

9 enrolled 10 charts

Neoplasm Metastasis, Endometrial Neoplasms

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

60 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04430699 2026-03-19

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

24 enrolled

Vulvar Neoplasms

NCT05231122 2026-03-16

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

80 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1 Completed

62 enrolled 17 charts

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04712851 2026-03-10

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

25 enrolled

Uterine Cervical Dysplasia

NCT05467670 2026-03-04

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

16 enrolled

Ovarian Neoplasms

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

20 enrolled

Ovarian Neoplasms

NCT05603910 2026-02-24

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Phase 1 Recruiting

18 enrolled

Endometrial Neoplasms

NCT07410676 2026-02-18

EBNK-ST-001

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

83 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Phase 1/2 Active not recruiting

24 enrolled 59 charts

Ovarian Cancer Recurrent

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

38 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05761951 2026-02-11

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

8 enrolled

Endometrial Neoplasms

NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

32 enrolled

Phase 1 Active not recruiting

Endometrial Neoplasms

NCT03932409 2026-02-10

FIERCE

45 enrolled

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT05082259 2026-02-10

ASTEROID

Phase 1 Recruiting

61 enrolled

BreastGynecologic

Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

87 enrolled

Adenocarcinoma, Uterine Cervical Neoplasms

NCT06640283 2025-12-24

ANA

GastrointestinalGynecologic

150 enrolled

Anal Canal Carcinoma, Uterine Cervical Neoplasms

NCT06266338 2025-12-22

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

30 enrolled

Uterine Cervical Neoplasms

NCT07261683 2025-12-19

Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

20 enrolled

Ovarian Neoplasms

NCT05296512 2025-12-16

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

30 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Ovarian Clear Cell Carcinoma

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT04865887 2025-10-07

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

35 enrolled

Uterine Cervical Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Phase 2 Terminated

4 enrolled 8 charts

Recurrence, Endometrial Neoplasms

NCT03029403 2025-09-19

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

47 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04387227 2025-09-18

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

22 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05156268 2025-08-17

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

26 enrolled

GynecologicSarcoma

Endometrial Carcinosarcoma

NCT06543576 2025-08-15

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

35 enrolled

Cervical Adenocarcinoma

NCT05114421 2025-08-07

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

30 enrolled

High Grade Fallopian Tube Serous Adenocarcinoma

NCT06513624 2025-07-25

ETC-159-02

Phase 1 Recruiting

16 enrolled

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

NCT03113487 2025-07-20

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

29 enrolled 11 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Recurrent Platinum-Resistant Fallopian Tube Carcinoma

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

19 enrolled

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02635360 2025-07-03

Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer

94 enrolled 16 charts

Uterine Cervical Neoplasms

NCT02899793 2025-06-11

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

25 enrolled 15 charts

Endometrial Neoplasms

NCT02520154 2025-06-08

Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

31 enrolled 12 charts

BreastDermatologicGenitourinaryGynecologicThoracic

Fallopian Tube Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04575961 2025-05-23

PERCEPTION

33 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Cystadenocarcinoma, Serous

NCT03835819 2025-05-15

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

18 enrolled 17 charts

Endometrial Neoplasms

NCT04483544 2025-04-29

Pembrolizumab and Olaparib in Cervical Cancer Patients

Phase 2 Terminated

8 enrolled 13 charts

Uterine Cervical Neoplasms

NCT06502743 2025-04-03

PENELOPE

92 enrolled

Endometrial Neoplasms

NCT02644369 2025-03-26

INSPIRE

BreastDermatologicGynecologic

100 enrolled

Carcinoma, Ovarian Epithelial, Melanoma, Triple Negative Breast Neoplasms

NCT04357873 2025-02-19

PEVOsq

GastrointestinalGenitourinaryGynecologicHead & Neck

112 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Penile Neoplasms, Vulvar Neoplasms, Neoplasms, Squamous Cell

NCT06805864 2025-02-03

BROTHER

Phase 2 Not yet recruiting

45 enrolled

Uterine Cervical Neoplasms

NCT02630823 2025-01-03

MK-3475 Immunotherapy in Endometrial Carcinoma

Phase 1 Completed

10 enrolled 9 charts